What is “osteonecrosis of the jaw” and how does Prolia relate?
Osteonecrosis of the jaw (ONJ) is a condition where bone in the jaw does not heal properly, often after dental procedures or trauma. Prolia (denosumab) is linked to ONJ risk in a way similar to other antiresorptive medicines, because it affects bone remodeling and turnover. Patients taking Prolia who need invasive dental work are the group most commonly associated with ONJ events [1].
How common is ONJ in people taking Prolia?
ONJ is uncommon, but it is a known risk with denosumab products. The likelihood is higher in people who have been on antiresorptive therapy for longer periods, have cancer treated with bone-targeted drugs (higher doses), or have major dental disease or need extractions/implants [1].
Who is at higher risk of ONJ while on Prolia?
Risk is higher when there are triggers such as invasive dental procedures (especially tooth extractions), poor oral hygiene, existing periodontal disease, ill-fitting dentures, and concurrent risk factors like smoking or diabetes. The risk also increases with duration and with higher-intensity oncologic bone therapies that use denosumab [1].
What symptoms should patients watch for?
People are typically advised to report warning signs such as jaw pain, swelling, exposed bone that does not heal, loose teeth, drainage, or bad taste/odor. Symptoms may start after dental work and can develop even if the patient has only minor jaw discomfort at first [1].
Does getting dental treatment while on Prolia cause ONJ?
Dental procedures that involve drilling or removing bone (extractions, implants, some periodontal surgeries) can increase risk. This is why clinicians generally coordinate dental work with the prescribing team when a patient is on Prolia, especially if treatment is long-running or there is significant dental disease [1].
How is ONJ diagnosed and treated?
Diagnosis is based on clinical findings (exposed or visible jaw bone that fails to heal) and the clinical context. Treatment usually focuses on preventing worsening and controlling infection or inflammation, often with oral hygiene measures, antimicrobial mouth rinses or antibiotics when appropriate, pain control, and referral to an oral surgeon/maxillofacial specialist. Some cases require debridement or other surgery depending on severity [1].
Can ONJ be prevented in Prolia patients?
Common prevention steps include a dental evaluation before starting therapy when possible, completing necessary invasive dental work ahead of time, maintaining excellent oral hygiene, and promptly addressing gum disease. If invasive dental work is needed during Prolia treatment, clinicians typically weigh the dental need against ONJ risk and involve dental/oral surgery specialists [1].
Does ONJ risk differ between Prolia (osteoporosis dose) and cancer-dose denosumab?
Yes. Denosumab has different dosing regimens across conditions. The risk profile for ONJ is generally considered higher with cancer-related dosing and longer exposure, compared with lower-dose osteoporosis use, but ONJ remains a recognized risk even in osteoporosis patients [1].
What should patients discuss with their doctor before starting or continuing Prolia?
Patients often need a plan that includes whether they should have a dental exam first, whether any extractions or major procedures should be completed beforehand, and how ongoing dental care will be managed during treatment. If ONJ symptoms occur, prompt evaluation is important [1].
---
Sources
- https://www.fda.gov/media/108811/download